As the landscape of care evolves in multiple sclerosis (MS), clinicians continue their efforts in optimizing therapeutic approaches for patients. Investigating de-escalation of therapies, which involves transitioning patients from high or moderate efficacy disease-modifying therapies to lower efficacy ones to lower risk of adverse effects, has been a topic of interest.
CU Anschutz
Fitzsimons Building
13001 East 17th Place
Aurora, CO 80045